Sonoma pharmaceuticals reports second quarter 2023 financial results

International sales increased by 18% in the six months ended september 30, 2022 compared to the same period prior year gross profit percentage continues to trend upwards with the quarter ended september 30, 2022, coming in at 40% compared to 33% same period prior year operating loss for the quarter ended september 30, 2022 improved 24% or $233,000 compared to same period prior year boulder, co / accesswire / november 14, 2022 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its second fiscal quarter and six months ended september 30, 2022. "we are pleased that our second quarter results show continued progress toward profitability and the successful expansion of our business," said amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking